1.646.889.1200|info@lifescipublicrelations.com

Arqule sees strength in early BTK inhibitor data; shares rise on phase I CLL news

//Arqule sees strength in early BTK inhibitor data; shares rise on phase I CLL news

Arqule sees strength in early BTK inhibitor data; shares rise on phase I CLL news

Shares of Arqule Inc. (NASDAQ:ARQL) hit a 52-week high Friday on news that the company’s Bruton’s tyrosine kinase (BTK) inhibitor, ARQ-531, achieved partial responses in four of six heavily pretreated people with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) during an ongoing phase I trial.

By | 2019-06-17T09:48:31-04:00 June 17th, 2019|News|Comments Off on Arqule sees strength in early BTK inhibitor data; shares rise on phase I CLL news

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.